Shengnuo Pharmaceuticals-B(02257) issued an announcementmulticadearcadegame, Dai Xiaochang resigned as the group's chief strategy officer for personal reasons, effective May 17, 2024. Dr. Dai will continue to serve as executive director and agreed to serve as senior consultant for the group's drug development and commercialization.
